70. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE pan-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION

CNS metastasis has become a prominent driver of morbidity and mortality in recent years as new targeted therapies have improved systemic outcomes. Mutations in the ErbB family of kinases are known oncodrivers in many of these cancers. ErbB family member “crosstalk” is associated with rapid developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheeler, Helen, Bacha, Jeffrey, Kanekal, Sarath, Pedersen, Harry, Sankar, Neil, Wang, Shen, Nesbit, Ian, Skoff, Kathy, Brown, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401413/
http://dx.doi.org/10.1093/noajnl/vdaa073.057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401413/
http://dx.doi.org/10.1093/noajnl/vdaa073.057

Ejemplares similares